SIMONE FAYBYSHEV: Open Payments
NPI 1861056178 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$342 in 14 payments from 7 companies in 2025. Trend: 2023 $1,003 · 2024 $1,068 · 2025 $342
Food & beverage: $342
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 5 | $121 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $61 |
| Lilly USA, LLC | 2 | $45 |
| AstraZeneca Pharmaceuticals LP | 2 | $40 |
| Astellas Pharma US Inc | 1 | $30 |
| GlaxoSmithKline, LLC. | 1 | $25 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $19 |
Products named: Kerendia, MOUNJARO, Veozah, TRELEGY ELLIPTA, AIRSUPRA, XIFAXAN, FARXIGA.
Industry payments across NY — which companies pay providers there.
